What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

21
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

TAGS:

description

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer. Program Goals. Ovarian Cancer Overview. PARP Inhibition in Ovarian Cancer. Testing for BRCA1/2 Mutations. PARP Inhibitors Under Development. Olaparib in Patients With BRCA1 / BRCA2 Ovarian Cancer. - PowerPoint PPT Presentation

Transcript of What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Page 1: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

What Does BRCA Have to Do With It? PARP Inhibitors in

Ovarian Cancer

Page 2: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
Page 3: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Program Goals

Page 4: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Ovarian Cancer Overview

Page 5: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibition in Ovarian Cancer

Page 6: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Testing for BRCA1/2 Mutations

Page 7: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibitors Under Development

Page 8: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Olaparib in Patients With BRCA1/BRCA2 Ovarian Cancer

Page 9: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibitors in Patients With BRCA1/BRCA2 Ovarian Cancer

Page 10: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibitors as Maintenance Therapy

Page 11: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Biomarkers to Measure PARP Inhibitor Response

Page 12: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibitors and Chemotherapy

Page 13: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Olaparib Maintenance Therapy

Page 14: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Velaparib in Patients With Recurrent Disease

Page 15: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Major Toxicities of PARP Inhibitors

Page 16: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Outstanding Questions

Page 17: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Abbreviations

Page 18: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

References

Page 19: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

References (cont)

Page 20: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

References (cont)

Page 21: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

References (cont)


MOVING FROM PARP INHIBITION TO€¦ · 5 PARP INHIBITION IN THE TREATMENT OF CANCER • Four PARP inhibitors have been approved for use in the treatment of ovarian and breast cancer

MOVING FROM PARP INHIBITION TO€¦ · 5 PARP INHIBITION IN THE TREATMENT OF CANCER • Four PARP inhibitors have been approved for use in the treatment of ovarian and breast cancer

BRCA Testing for Hereditary Breast & Ovarian Cancers€¦ · Pancreatic cancer Prostate cancer. The BRCA gene impact BRCA test by MedGenome Unaffected ... • An individual with triple

BRCA Testing for Hereditary Breast & Ovarian Cancers€¦ · Pancreatic cancer Prostate cancer. The BRCA gene impact BRCA test by MedGenome Unaffected ... • An individual with triple

Stage IIIB Epithelial Ovarian Cancer: Recurrent 13 Months … · 2018-05-23 · sensitive ovarian cancer released this year are related to PARP inhibitors. PARP inhibitors are key

Stage IIIB Epithelial Ovarian Cancer: Recurrent 13 Months … · 2018-05-23 · sensitive ovarian cancer released this year are related to PARP inhibitors. PARP inhibitors are key

EP-100 sensitizes BRCA wild-type ovarian cancer cells to ...

EP-100 sensitizes BRCA wild-type ovarian cancer cells to ...

Ovarian Cancer Overview for Health Care Providers group · • 2) Site-Specific Ovarian Cancer ... BRCA 1 Hereditary Breast and Ovarian Cancer . ... • RMI= U/S score x menopausal

Ovarian Cancer Overview for Health Care Providers group · • 2) Site-Specific Ovarian Cancer ... BRCA 1 Hereditary Breast and Ovarian Cancer . ... • RMI= U/S score x menopausal

Platinum Agents, Taxanes and PARP Inhibitors: The Ovarian ... · other cancers, ovarian cancer harbors its own staging system known as FIGO staging (Table 1). Upon confirmation of

Platinum Agents, Taxanes and PARP Inhibitors: The Ovarian ... · other cancers, ovarian cancer harbors its own staging system known as FIGO staging (Table 1). Upon confirmation of

HIGHLIGHTS OF PRESCRIBING INFORMATION ... · Study 10 (NCT01482715) and ARIEL2 (NCT01891344), in patients with advanced BRCA-mutant ovarian cancer who had progressed after 2 or more

HIGHLIGHTS OF PRESCRIBING INFORMATION ... · Study 10 (NCT01482715) and ARIEL2 (NCT01891344), in patients with advanced BRCA-mutant ovarian cancer who had progressed after 2 or more

Clinical Cancer Research - PARP Inhibitors: Extending ... · PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers Patrick G. Pilie1, Carl M. Gay2, Lauren A. Byers2, Mark

Clinical Cancer Research - PARP Inhibitors: Extending ... · PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers Patrick G. Pilie1, Carl M. Gay2, Lauren A. Byers2, Mark

Update on PARP inhibitors: opportunities and challenges in ... · carcinoma ovarico “platino sensibile” con mutazioni germinali o somatiche di BRCA . Can PARP inhibitors replace

Update on PARP inhibitors: opportunities and challenges in ... · carcinoma ovarico “platino sensibile” con mutazioni germinali o somatiche di BRCA . Can PARP inhibitors replace

Hereditary ovarian cancer - CORE · surveillance in high-risk women having a strong family history or BRCA mutation carriers include transvaginal pelvic ultrasound with color Doppler

Hereditary ovarian cancer - CORE · surveillance in high-risk women having a strong family history or BRCA mutation carriers include transvaginal pelvic ultrasound with color Doppler

Prioritizing variants in complete Hereditary Breast and ...€¦ · Prioritizing variants in complete Hereditary Breast and Ovarian Cancer (HBOC) genes in patients lacking known BRCA

Prioritizing variants in complete Hereditary Breast and ...€¦ · Prioritizing variants in complete Hereditary Breast and Ovarian Cancer (HBOC) genes in patients lacking known BRCA

Ovarian Cancer Awareness Month...2007/04/09  · 6 + #OvarianCancer Risk Factors Family history - Approximately 15% of ovarian cancer cases are due to the BRCA or other gene mutations.

Ovarian Cancer Awareness Month...2007/04/09  · 6 + #OvarianCancer Risk Factors Family history - Approximately 15% of ovarian cancer cases are due to the BRCA or other gene mutations.

Synthetic Lethality of PARP Inhibitors in Combination with ... · Translational Science Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA

Synthetic Lethality of PARP Inhibitors in Combination with ... · Translational Science Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA

BRCA 2020 - 2020 BRCA Symposium · BRCA 2020 The Eighth International Symposium on Hereditary Breast and Ovarian Cancer ... Beyond the current models MODERATORS: Lawrence Brody, PhD,

BRCA 2020 - 2020 BRCA Symposium · BRCA 2020 The Eighth International Symposium on Hereditary Breast and Ovarian Cancer ... Beyond the current models MODERATORS: Lawrence Brody, PhD,

Significato clinico di BRCA in ovarian cancermedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/20160615RM_32... · Sistema nervoso centrale (6%) Ovaio (7%) Stomaco (6%) 70000 donne

Significato clinico di BRCA in ovarian cancermedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/20160615RM_32... · Sistema nervoso centrale (6%) Ovaio (7%) Stomaco (6%) 70000 donne

Understanding Hereditary Breast & Ovarian Cancer – … · 4 understanding hereditary breast & ovarian cancer – the brca genes understanding hereditary breast & ovarian cancer

Understanding Hereditary Breast & Ovarian Cancer – … · 4 understanding hereditary breast & ovarian cancer – the brca genes understanding hereditary breast & ovarian cancer

UNDERSTANDING GENETICS, BRCA AND PARP INHIBITORS GUIDEBOOK · Understanding Genetics, BRCA and PARP Inhibitors Guidebook 7 result may confirm a diagnosis, indicate that a person is

UNDERSTANDING GENETICS, BRCA AND PARP INHIBITORS GUIDEBOOK · Understanding Genetics, BRCA and PARP Inhibitors Guidebook 7 result may confirm a diagnosis, indicate that a person is

Breast and Ovarian Cancer: Risk Assessment and Prevention ......BRCA mutation Ovarian cancer (any age) Young breast cancer ( < 45 years; < 50 if small family) Multiple cases

Breast and Ovarian Cancer: Risk Assessment and Prevention ......BRCA mutation Ovarian cancer (any age) Young breast cancer ( < 45 years; < 50 if small family) Multiple cases

PARP Inhibitors for Ovarian Cancer · PDF fileAstra Zeneca Pharmaceuticals LP;2017. Rucaparib (Rubraca®)[package insert].Boulder, CO. Clovis ... Dyspnea Photosensitivity ≥ 20% Hypertension

PARP Inhibitors for Ovarian Cancer · PDF fileAstra Zeneca Pharmaceuticals LP;2017. Rucaparib (Rubraca®)[package insert].Boulder, CO. Clovis ... Dyspnea Photosensitivity ≥ 20% Hypertension

BRCA Testing in Ovarian cancer Arabic Approach ElKhalfaoui BRCA...Norquist, JAMA 2016 Cancer Risk in Carriers Estimated Cumulative Risks of Breast and Ovarian Cancer in Mutation Carriers

BRCA Testing in Ovarian cancer Arabic Approach ElKhalfaoui BRCA...Norquist, JAMA 2016 Cancer Risk in Carriers Estimated Cumulative Risks of Breast and Ovarian Cancer in Mutation Carriers